Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Statins and genetic inhibition of the mevalonate pathway activate an ATF3-STMN2 regenerative program.

bioRxiv : the preprint server for biology·2026
Same author

Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Higher integration scores are associated with facial emotion perception differences in dissociative identity disorder.

Journal of psychiatric research·2020
Same author

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.

Cancer research·2019
Same author

The reverse translation of a quantitative neuropsychiatric framework into preclinical studies: Focus on social interaction and behavior.

Neuroscience and biobehavioral reviews·2019
Same author

Hippocampal place cell dysfunction and the effects of muscarinic M<sub>1</sub> receptor agonism in a rat model of Alzheimer's disease.

Hippocampus·2018

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Evan P Lebois1, Chinnappa D Kodira1, Robert D Hubbard2

  • 1Violet Therapeutics, Somerville, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

像VT-001这样的小分子EPHB3抑制剂,通过减少神经炎症和改善阿尔茨海默氏症患者的行为缺陷,显示出治疗神经退行性疾病的前景.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 分子生物学分子生物学

背景情况:

  • 大脑的质细胞,特别是星球细胞和微质细胞,是阿尔茨海默病 (AD) 病原体的关键驱动因素.
  • EPHB3被确定为一种通过天体细胞-微细胞相互作用调解神经炎症的新型点.
  • 小分子EPHB3抑制剂是为了向这些星球细胞介导的疾病机制而开发的.

研究的目的:

  • 为了测试治疗假设,EPHB3抑制可以减弱AD模型中的反应性天体细胞特征.
  • 评估EPHB3抑制剂降低神经炎症和拯救行为缺陷的潜力.
  • 评估新型小分子EPHB3抑制剂在粉样化病 (5xFAD) 和病 (PS19) 的小鼠模型中的疗效.

主要方法:

  • 合成和特征小分子EPHB3抑制剂使用体外激酶和细胞纳米BRET测试.
  • 在EAE,5xFAD和PS19模型中证明VT-001的药理动力学/药理动力学 (PK/PD) 特性和体内疗效.
  • 使用单细胞RNA-seq,蛋白质组学和免疫光学,以及行为监测,评估VT-001对天体细胞和微质细胞机制的影响.

主要成果:

  • 在EAE,5xFAD和PS19模型中,VT-001显著挽救了行为缺陷和减弱的神经炎症.
  • 疗效与减少的反应性天体细胞特征,神经炎症基因和Aβ斑块诱导的基因组有关.
  • VT-001表现出良好的耐受性和中枢神经系统 (CNS) 暴露;确定了下一代抑制剂VT-002.

结论:

  • VT-001是一种强效和选择性的EPHB3抑制剂,在神经炎症和神经退行模型中具有显著的体内疗效.
  • EPHB3 抑制剂,特别是 VT-001,为神经退行性疾病提供了一个有前途的治疗策略.
  • 通过EPHB3抑制准星细胞介导疾病机制,提供了一个新的治疗机会.